HRMY

AI Memo

Harmony Biosciences

As of 2026-10-24/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-24 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

BP-205 multiple-ascending-dose data • 2026-12-31

Base target: $39 / p=45% prob

Biggest risk

Revenue remains concentrated in WAKIX, the pipeline faces clinical and regulatory uncertainty, and the CEO transition adds execution risk [#SEC-8K-2026-08-04] [#8-K-2026-10-13].

Invalidation

Break below $26 or thesis failure.

What would change my mind?

WAKIX growth and patient gains support the reiterated 2026 revenue range, while favorable BP-205 data and pitolisant GR progress could broaden the franchise [#SEC-8K-2026-08-04].

Research note

Recommendation

—

Confidence

medium

As of

2026-10-24

Base target

$39

p=45%

Bull target

$49

p=30%

Bear target

$26

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

WAKIX revenue versus 2026 guidance
Pitolisant HD Phase 3 topline data
WAKIX growth and patient gains support the reiterated 2026 revenue range, while favorable BP-205 data and pitolisant GR progress could broaden the franchise [#SEC-8K-2026-08-04].

BearKey bullets

BP-205 data may disappoint on safety, tolerability, or development prospects; efficacy is not yet established [#SEC-8K-2026-08-04].
CEO succession could disrupt commercial or pipeline execution despite management's stated expectation of unchanged milestone timing [#8-K-2026-10-13].
No verified post-announcement analyst revisions or direct valuation-peer set is available.

WatchKey bullets

BP-205 multiple-ascending-dose data

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $39 (p=45%)

Target spread vs base: +26% / -33%

Scenario probabilities

Bull Target: $49 (p=30%)Base Target: $39 (p=45%)Bear Target: $26 (p=25%)

Commentary

Company-source operating evidence is constructive, but the leadership change tempers conviction. The packet's price anchors fell from $38.27 on October 15 to $36.13 on October 23, about 5.6%; those anchors alone do not establish the cause. The stored earnings-document row is chiefly about Editas and is not an official Harmony earnings release. Reliable post-transition analyst revisions, social coverage, options skew, short interest, and employee readings were not supplied; zero-valued sentiment fields mean unavailable, not neutral.

As of 2026-10-24 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

WAKIX growth and patient gains support the reiterated 2026 revenue range, while favorable BP-205 data and pitolisant GR progress could broaden the franchise [#SEC-8K-2026-08-04].

Bear Case

Revenue remains concentrated in WAKIX, the pipeline faces clinical and regulatory uncertainty, and the CEO transition adds execution risk [#SEC-8K-2026-08-04] [#8-K-2026-10-13].

Drivers

Scannable catalysts and supporting factors

WAKIX revenue versus 2026 guidance
Pitolisant HD Phase 3 topline data

Scenarios

Bull Target (Scenario probability)

$49 / p=30% prob

Base Target (Scenario probability)

$39 / p=45% prob

Bear Target (Scenario probability)

$26 / p=25% prob

Analysis 2026-10-24 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
BP-205 multiple-ascending-dose data
Harmony says Phase 1 multiple-ascending-dose data remain on track for Q4 2026. Results may change confidence in BP-205's development prospects, but clinical efficacy remains unproven [#SEC-8K-2026-08-04] [#8-K-2026-10-13].
Prob 65.00% • Move 10.00% • Priced-in 40.00%
EVENT2027-01-01
CEO succession
Peter Anastasiou is scheduled to succeed Jeffrey Dayno as CEO on January 1, 2027. Harmony reiterated revenue guidance and BP-205 timing alongside the announcement, but execution continuity still needs to be demonstrated [#8-K-2026-10-13].
Prob 90.00% • Move -3.00% • Priced-in 70.00%
EVENT2027-04-01
Pitolisant GR regulatory decision
Harmony reported that the pitolisant GR NDA was accepted, with a target PDUFA date of April 1, 2027. Approval and the eventual label remain uncertain [#SEC-8K-2026-08-04].
Prob 55.00% • Move 12.00% • Priced-in 40.00%

Short-term Catalysts

Next few weeks

WAKIX revenue versus 2026 guidance
2026-12-31
Q2 WAKIX revenue reached $261.3 million, up 30% year over year, and estimated average patients rose to 8,950. Delivery against reiterated full-year revenue guidance of $1.0 billion–$1.04 billion is the near-term commercial test [#SEC-8K-2026-08-04] [#8-K-2026-10-13].
Prob 70% • Move 6% • Priced-in 65%

Long-term Catalysts

Months to a year

Pitolisant HD Phase 3 topline data
2027-12-31
Harmony said pitolisant HD remained on track for Phase 3 topline data in 2027. The broad timing and binary clinical outcome warrant a longer-horizon, lower-conviction view [#SEC-8K-2026-08-04].
Prob 55% • Move 10% • Priced-in 30%

Risks

BP-205 data may disappoint on safety, tolerability, or development prospects; efficacy is not yet established [#SEC-8K-2026-08-04].
CEO succession could disrupt commercial or pipeline execution despite management's stated expectation of unchanged milestone timing [#8-K-2026-10-13].
No verified post-announcement analyst revisions or direct valuation-peer set is available.
Pitolisant GR may face delay or an unfavorable regulatory decision, and pitolisant HD Phase 3 data remain uncertain [#SEC-8K-2026-08-04].
WAKIX revenue could miss the reiterated $1.0 billion–$1.04 billion 2026 range [#8-K-2026-10-13].

Peers

Symbol	Summary
BHVN	Similar sector and approximate market capitalization in the packet, but direct indication, product-stage, and commercial comparability to Harmony is not established. Use only as a loose size comparator.
IMNM	Similar sector and approximate market capitalization in the packet, but no direct CNS-franchise comparability is established. Not a reliable direct valuation peer.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-24

Loading AI feed…

Symbol

Summary

BHVN

Similar sector and approximate market capitalization in the packet, but direct indication, product-stage, and commercial comparability to Harmony is not established. Use only as a loose size comparator.

IMNM

Similar sector and approximate market capitalization in the packet, but no direct CNS-franchise comparability is established. Not a reliable direct valuation peer.